A Combination Approach for Treatment of Castration-Resistant Prostate Cancer

Abstract

Abiraterone, enzalutamide, and taxanes are first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). They prolonged overall survival of the patients. However, both de novo and acquired resistance are common. Accumulating evidence has indicated a role of androgen receptor splice variants (AR-Vs) in mediating resistance to these therapies. The purpose of this study is to develop 20(S)-protopanaxadiol-aglycone (PPD), which we showed to downregulate the levels and activities of AR-Vs, as an antidote to overcome resistance to these therapies. We showed that PPD might attenuate AR-V homodimerization and that combined treatment with PPD and enzalutamide might be more efficacious than enzalutamide alone in inhibiting the growth of CRPC tumors.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2016
Accession Number
AD1034290

Entities

People

  • Yan Dong

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Antidotes
  • Biomedical Research
  • Castration
  • Cells
  • Culture Techniques
  • Department Of Defense
  • Diseases And Disorders
  • Electronic Mail
  • Inhibition
  • Medical Personnel
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Resistance

Fields of Study

  • Biology

Readers

  • Prostate Cancer Biology.